U.S. markets close in 3 hours 6 minutes

Aziyo Biologics, Inc. (AZYO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
7.26+0.14 (+1.91%)
As of 11:17AM EDT. Market open.

Aziyo Biologics, Inc.

12510 Prosperity Drive
Suite 370
Silver Spring, MD 20904
United States
240 247 1170

IndustryMedical Devices
Full Time Employees176

Key Executives

NameTitlePayExercisedYear Born
Mr. Kevin L. Rakin M.B.A, M.S.Exec. Chairman77.5kN/A1961
Dr. C. Randal Mills Ph.D.Co-Founder, Pres & CEO and Director65kN/A1972
Mr. Matthew B. FergusonChief Financial Officer356.64kN/A1968
Mr. Ronald K. LloydExec. Officer545.97kN/A1961
Mr. Thomas EngleseChief Commercial Officer396.11kN/A1974
Dr. Darryl Roberts Ph.D.Exec. VP of Operations & Product Devel.N/AN/A1962
Mr. Peter G. Edwards Esq.Gen. CounselN/AN/A1961
Ms. Courtney GuyerVP of MarketingN/AN/AN/A
Dr. Jerome Riebman FACC, M.A., M.D.Chief Medical OfficerN/AN/A1954
Mr. Jeffry D. HametVP of Fin., Treasurer & Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Corporate Governance

Aziyo Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.